Literature DB >> 8245437

Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation.

M A Bowen1, K J Olsen, L Cheng, D Avila, E R Podack.   

Abstract

Studies are described revealing novel regulatory functions for the lymphocyte activation Ag CD30. A new mAb, C10, reactive with YT cells binds to CD30 and induces inhibition of the cytotoxicity of YT for Raji cells. C10 inhibition of cytotoxicity requires several hours preincubation of YT with C10; the antibody has no effect if added directly to YT cytotoxicity assays. CD30 stimulation by C10 down-regulates CD28 expression on YT by > 80% within 48 h. Because CD28 is required for YT cytotoxicity toward Raji cells and other B7/BB1 bearing targets, it is suggested that inhibition of cytotoxicity of YT is mediated by control of CD28 expression and/or signaling via CD30. Accordingly, conjugation of YT with Raji is only slightly affected by CD30-mediated down-regulation of CD28, and perforin mRNA steady state levels are not changed at all. C10 treatment of YT cells additionally down-regulates the expression CD45 and up-regulates IL-2R p55. Moreover, CD30 stimulation by C10 causes homotypic aggregation of YT. Homotypic aggregation is slow, requiring gene transcription, translation, metabolic energy at elevated temperature (37 degrees C), magnesium ions, and an intact cytoskeleton. These studies offer insights into the function of CD30 as a complex regulator of T cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8245437

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene.

Authors:  E J Croager; A M Gout; L J Abraham
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2.

Authors:  E N Tsitsikov; D A Wright; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

3.  Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.

Authors:  A Cerutti; A Schaffer; R G Goodwin; S Shah; H Zan; S Ely; P Casali
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

4.  Lipopolysaccharide-dependent down-regulation of CD27 expression on T cells activated with superantigen.

Authors:  K Kai; H Rikiishi; S Sugawara; M Takahashi; H Takada; K Kumagai
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

5.  CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule.

Authors:  U Latza; H D Foss; H Dürkop; F Eitelbach; K P Dieckmann; V Loy; M Unger; G Pizzolo; H Stein
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

6.  Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells.

Authors:  A Cerutti; E C Kim; S Shah; E J Schattner; H Zan; A Schaffer; P Casali
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

Review 7.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

Review 8.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

9.  Critical roles of CD30/CD30L interactions in murine autoimmune diabetes.

Authors:  S Chakrabarty; M Nagata; H Yasuda; L Wen; M Nakayama; S A Chowdhury; K Yamada; Z Jin; R Kotani; H Moriyama; O Shimozato; H Yagita; K Yokono
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

10.  Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand.

Authors:  M A Bowen; D D Patel; X Li; B Modrell; A R Malacko; W C Wang; H Marquardt; M Neubauer; J M Pesando; U Francke
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.